ATCC | THE ESSENTIALS OF LIFE SCIENCE RESEARCH GLOBALLY DELIVERED™

cell passages

Tumor cell panels are valuable research models for cancer research, drug discovery, compound screening, biomarker selection, pathway analysis, and functional genomics. With sufficient genetic diversity represented in each of these panels, they are also ideal experimental tools for investigating the effects of somatic mutations on drug sensitivity and resistance. The ATCC collection of tumor cell panels include Tissue-Specific Tumor Cell Panels, such as the Breast Cancer Cell Panels, the Lung Cancer Panel, the Liver Cancer Panel, and the Pancreatic Cancer Cell Panels, as well as Molecular Signature Panels, such as the p53 Hotspot Mutation Cell Panels.

This month, Cell Passages will feature a new type of tumor cell panels - the ATCC Genetic Alteration Panels. Also, be sure to download the ATCC Tumor Cell Panel Brochure, which is organized by gene mutations and tissue origin, and visit the ATCC website for other cell biology resources.

ATCC Genetic Alteration Panels – *Now Available!*

The newly created ATCC Genetic Alteration Panels are organized around genes that have important implications for cancer research.

The cell lines in each of these panels were selected because they carried a specific mutation or deletion, or because they exhibited gene amplification in the featured gene. Moreover, the mutational status of the cell lines in these panels have been sequenced and validated by ATCC.

Learn more or order these ATCC genetic alteration panels:

- EGFR (ATCC® TCP-1027™)
- PI3K (ATCC® TCP-1028™)
- AKT (ATCC® TCP-1029™)
- PTEN (ATCC® TCP-1030™)
- RAS (ATCC® TCP-1031™)
- BRAF (ATCC® TCP-1032™)
- ERK (ATCC® TCP-1033™)
- FGFR (ATCC® TCP-1034™)
- MYC (ATCC® TCP-1035™)
- MET (ATCC® TCP-1036™)

Share with others:

News this Month

ATCC Publications



Human KRAS DNA Certified Reference Material (CRM) *Now Available!*

We are pleased to announce the availability of our new KRAS CRM nucleic acids. These products represent the common mutations observed in tumor biology and include a wild type KRAS CRM control.

ATCC® CRM-CCL-185D™ (derived from A549),

ATCC® CRM-CCL-119D™ (derived from CCRF-CEM),

ATCC® CRM-HTB-26D™ (derived from MDA-MB-231),

ATCC® CRM-CRL-1420D™ (derived from MIA PaCa-2),

ATCC® CRM-CRL-3211D™ (derived from PSN 1), and

ATCC® CRM-TIB-161D™ (derived from HuT78).

Find more CRM

Meet us at the SLAS2014 Annual Conference in San Diego

January 18 - 22

ATCC is featuring specific cell-based solutions for screening at SLAS2014, the 3rd Annual Conference and Exhibition of the Society for Laboratory Automation and Screening. Visit us at booth #1348 for helpful information on hTERT immortalized cell lines, human stem cells, cancer cell panels, and reagents that are particularly suited for screening and drug discovery research.

Visit ATCC Booth #1348

Webinar – ATCC - Sophisticated Approaches to *In Vitro* Research

Presenter: John Pulliam, Ph.D.

ATCC Field Application Scientist

February 6, 2014

This webinar will provide an overview of the services that ATCC offers to the scientific community. We will also discuss the sophisticated approaches of utilizing Genetic Alteration Panels, hTERT immortalized cells, and the HEKPlus system for protein production.

Register for a session
10:00 AM or 3:00 PM (EST).

FAQs

Q: Is there a control cell line included in the tumor cell panels?

A: It depends on the individual panel. The Molecular Signature Panels, which focuses on cancer genes or key component of cell signaling pathways, have either included a control cell line that is wild type for a specific gene (such as the p53 hotspot mutation cell panels) or recommends a number of wild type control cell lines that can be ordered separately within the panel datasheet (such as the EGFR genetic alteration tumor cell panel).

Have more questions?

ATCC - 10801 University Boulevard, Manassas, VA 20110